Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHT101 in Relapsed/Refractory T-Cell and B-Cell Hematological Malignancies
NCT07809126Phase 1Not yet recruiting
- Sponsor
- Nanjing Miracle Biotechnology
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CHT101 in hematological malignancies, sponsored by Nanjing Miracle Biotechnology. Primary endpoints: Maximum Tolerated Dose at Day 28 and Adverse Events and Serious Adverse Events up to 24 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
CHT101
03
Conditions
hematological malignancies
Beyond the preview
Go deeper on NCT07809126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07809126.